Therapy Directory

Carboplatin clinical trials

Directory of U.S. ClinicalTrials.gov public records that list Carboplatin as a study intervention. Browse Carboplatin recruiting trials, filter by phase, sponsor, or location, and open the official ClinicalTrials.gov study record for each result.

ClinicalTrials.gov public records Last synced Nov 6, 2026, 6:48 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Official matching trials

1999

Shown on this page

Current sort

Live official records

Open in full search

Conditions: Breast Cancer, Adenocarcinoma of the Breast
Interventions: PBI with sequential chemotherapy, PBI with concurrent chemotherapy; Other
Lead sponsor: Richard Zellars; Other
Eligibility: 18 Years to 100 Years · Female only
Enrollment: 81 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2028
U.S. locations: 10
States / cities: Washington D.C., District of Columbia • Fort Wayne, Indiana • Indianapolis, Indiana + 6 more

Conditions: Breast Cancer
Interventions: carboplatin, paclitaxel albumin-stabilized nanoparticle formulation, vorinostat, placebo; Drug · Other
Lead sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins; Other
Eligibility: 18 Years and older · Female only
Enrollment: 68 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2027
U.S. locations: 5
States / cities: Birmingham, Alabama • Indianapolis, Indiana • Annapolis, Maryland + 2 more

Conditions: Head and Neck Cancer, HPV
Interventions: Volrustomig, Carboplatin, Paclitaxel; Drug
Lead sponsor: University of Chicago; Other
Eligibility: 18 Years and older
Enrollment: 38 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2029
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Small-cell Lung Cancer, Extensive-stage Small-cell Lung Cancer, Lung Cancer
Interventions: Ablative Radiation, Durvalumab, Etoposide, Carboplatin; Radiation · Drug
Lead sponsor: University of Chicago; Other
Eligibility: 18 Years and older
Enrollment: 49 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2027
U.S. locations: 2
States / cities: Chicago, Illinois • Madison, Wisconsin

Conditions: Stage 1 cT1b-T1cN0M0, Triple Negative Breast Cancer
Interventions: Carboplatin, Paclitaxel, Pembrolizumab, Doxorubicin, Cyclophosphamide; Drug
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 28 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 1
States / cities: Houston, Texas

Conditions: HPV-Related Squamous Cell Carcinoma
Interventions: Cemiplimab; Drug
Lead sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins; Other
Eligibility: 18 Years and older
Enrollment: 32 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2027
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Squamous Cell Carcinoma of the Head and Neck
Interventions: Cisplatin, Carboplatin, IMRT (Intensity-Modulated Radiation Therapy), Boost Radiation to Hypoperfused Volumes; Drug · Radiation
Lead sponsor: University of Michigan Rogel Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 106 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2023
U.S. locations: 2
States / cities: Ann Arbor, Michigan

Conditions: Non-Small Cell Lung Cancer
Interventions: Nivolumab; Drug
Lead sponsor: VA Office of Research and Development; Federal
Eligibility: 18 Years and older
Enrollment: 25 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2030
U.S. locations: 7
States / cities: West Haven, Connecticut • Washington D.C., District of Columbia • Indianapolis, Indiana + 4 more

Conditions: Metastatic Breast Cancer
Interventions: Enzalutamide, Mifepristone, TPC; Drug
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 201 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2027
U.S. locations: 12
States / cities: Birmingham, Alabama • San Francisco, California • Chicago, Illinois + 9 more

Conditions: Adenocarcinoma of the Lung, Adenosquamous Cell Lung Cancer, Large Cell Lung Cancer, Recurrent Non-small Cell Lung Cancer, Squamous Cell Lung Cancer, Stage IIA Non-small Cell Lung Cancer, Stage IIB Non-small Cell Lung Cancer, Stage IIIA Non-small Cell Lung Cancer, Stage IIIB Non-small Cell Lung Cancer
Interventions: hypofractionated radiation therapy, laboratory biomarker analysis, image-guided radiation therapy, carboplatin, paclitaxel, stereotactic body radiation therapy; Radiation · Other · Drug
Lead sponsor: Jonsson Comprehensive Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 29 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2028
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Carcinoma, Squamous Cell, Non-small-cell Lung
Interventions: Pembrolizumab, Carboplatin, Paclitaxel, Nab-paclitaxel, Olaparib, Placebo; Biological · Drug
Lead sponsor: Merck Sharp & Dohme LLC; Industry
Eligibility: 18 Years and older
Enrollment: 851 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2026
U.S. locations: 18
States / cities: Birmingham, Alabama • Burbank, California • Boca Raton, Florida + 15 more

Conditions: Carcinoma, Squamous Cell, Oral Cancer, Oropharynx Cancer, Larynx Cancer, Lip Cancer, Esophageal Cancer
Interventions: Durvalumab, Carboplatin, Nab-paclitaxel, Cisplatin, Surgical resection, IMRT; Drug · Procedure · Radiation
Lead sponsor: UNC Lineberger Comprehensive Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 39 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2027
U.S. locations: 2
States / cities: Chapel Hill, North Carolina • Nashville, Tennessee

About this Carboplatin clinical trials directory page

What this page lists: U.S. ClinicalTrials.gov public records that list Carboplatin as a study intervention, including recruiting, not yet recruiting, and active not recruiting trials.
How to narrow results: Use the filters above to scope by condition, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, age, or NCT ID within Carboplatin.
Where the data comes from: Records are sourced from the official ClinicalTrials.gov public API. Each result links back to the official study page, which is the source of truth for eligibility, enrollment, and contact information.
What this page does not do: No medical advice, eligibility judgments, treatment recommendations, ranking of trials by quality, or AI-generated medical summaries.

Carboplatin clinical trials

Filter and sort this therapy

Live official records

Partial Irradiation and Sequential vs. Concurrent Chemo Early Breast Cancer

Carboplatin and Nab-Paclitaxel With or Without Vorinostat in Treating Women With Newly Diagnosed Operable Breast Cancer

Response-Adaptive Treatment in Untreated Locoregional HPV-Negative Head and Neck Cancer

Durvalumab and Ablative Radiation in Small Cell Lung Cancer (DARES)

Open-label, Single Center, Single-arm, Phase 2 Study of Neoadjuvant Pembrolizumab in Combination With Carboplatin and Paclitaxel in Patients With Stage 1 cT1b-T1cN0M0 Triple Negative Breast Cancer

Trial of Cemiplimab, or Cemip-Chemo Followed by Biomarker-guided Treatment for Pts w/HPV H&N Ca

Randomized Phase II Study of DCE-MRI-based Dose Escalation for Poor-prognosis and Neck Cancer

Repositioning Immunotherapy in VetArans With Lung Cancer

A Study of Enzalutamide, Enzalutamide in Combination With Mifepristone, or Chemotherapy in People With Metastatic Breast Cancer

Image-Guided Hypofractionated Radiation Therapy With Stereotactic Body Radiation Therapy Boost and Combination Chemotherapy in Treating Patients With Stage II-III Non-Small Cell Lung Cancer That Cannot Be Removed By Surgery

A Study of Pembrolizumab (MK-3475) With or Without Maintenance Olaparib in First-line Metastatic Squamous Non-small Cell Lung Cancer (NSCLC, MK-7339-008/KEYLYNK-008)

Carboplatin, Nab-Paclitaxel, Durvalumab Before Surgery and Adjuvant Therapy in Head and Neck Squamous Cell Carcinoma

About this Carboplatin clinical trials directory page